astorya.vc

European insurtech is a small enough community that most of its investors know each other personally, and astorya.vc is among the more visible specialist funds in the category. Based in Paris and founded by ex-AXA and ex-Allianz operators, the firm writes pre-seed and seed checks into European companies building infrastructure, distribution, and adjacent technologies for the insurance industry. Healthcare relevance is real but bounded: digital health surfaces in the portfolio mostly through the lens of insurance and emerging-risk, rather than through clinical products or care delivery. Founders considering astorya.vc as a healthcare investor should calibrate accordingly.

The thesis at astorya is sharply defined. The firm invests in early-stage European companies with a clear insurtech relevance, including adjacent emerging-risk categories where new data and new models are reshaping how insurance is underwritten and distributed. The fund’s published positioning emphasizes founder operator credibility, European geographic focus across France, Germany, the United Kingdom, and Spain, and a willingness to lead or co-invest in pre-seed and seed rounds. Digital health exposure has come through companies whose data, distribution, or risk-modeling capabilities matter to insurers rather than through healthcare-only businesses. Founders building pure-play care delivery, hospital software, or clinical research products will find the firm’s mandate misaligned. Founders building products that touch insurance underwriting, claims, distribution, or risk data with a healthcare angle will find a more substantive conversation.

The portfolio includes Zelros, the Paris-based artificial intelligence platform for insurance distribution that has scaled across European insurance carriers, and Weecover, the Spanish embedded insurance infrastructure company. Celest Science also appears in the portfolio, reflecting the firm’s willingness to back deeptech and emerging-risk-adjacent companies whose underwriting relevance may develop over time. The portfolio’s center of gravity sits firmly in insurance infrastructure and distribution rather than in consumer health, and founders should set expectations about partner expertise accordingly.

Check sizes fall in the two-hundred-fifty-thousand to one-million-dollar range, modest by US pre-seed standards but appropriate for the European early-stage market where round sizes generally compress relative to American comparables. The firm leads or co-invests at pre-seed and seed and does not write Series A or growth checks. Reserves are deployed selectively into portfolio companies that have hit clear commercial milestones with European insurance carriers. Founders raising larger seed rounds should expect astorya to participate in a syndicate rather than to anchor.

Decision-making sits with the founding partners, Florian Graillot and Jan Kastory, both of whom bring operator backgrounds from large European insurance carriers. That structure means founders meeting astorya are speaking with decision-makers from the first conversation, and diligence is informed by direct operational experience inside the buyer organizations the portfolio companies are trying to sell to.

The most effective approach is a warm introduction through a European insurtech founder or through an insurance-industry operator known to the partners. Cold inbound is read but rarely prioritized. Founders should be specific about their European insurance commercial strategy and should be prepared to discuss carrier procurement, regulatory landscape across multiple European jurisdictions, and the realistic sales cycle for selling into established European insurers.

Founders should know that astorya is an insurtech specialist first and a healthcare investor only by adjacency. The firm’s value is highest for founders whose product is genuinely useful to insurers; the firm’s value is limited for founders building healthcare products that have only a notional insurance angle. Founders should resist the temptation to manufacture an insurance narrative to fit the firm’s thesis, because the partners will see through it quickly.